BIM-018

BIM-018 is a synthetic cannabinoid that is structurally related to JWH-018, which is known for its potent psychoactive effects. BIM-018 is a full agonist at both the CB1 and CB2 cannabinoid receptors, with a binding affinity of 1.2 nM at CB1 and 1.1 nM at CB2. It is one of the few synthetic cannabinoids to have been studied in animals, with studies showing it to have similar effects to THC, the main active component of cannabis.

Chemistry

BIM-018 is a derivative of JWH-018, with a phenylacetyl group replacing the naphthyl group of JWH-018. This change in structure results in a compound with similar binding affinity to the cannabinoid receptors, but with a different chemical structure. The exact synthesis of BIM-018 is not publicly available, but it is likely to involve a similar process to the synthesis of JWH-018, involving the reaction of a suitable phenylacetyl halide with a suitable indole derivative.

Pharmacology

BIM-018 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a slightly higher affinity for the CB1 receptor. This is similar to the action of THC, which is also a full agonist at both receptors. The psychoactive effects of BIM-018 are likely to be due to its action at the CB1 receptor, which is primarily located in the brain. The CB2 receptor is primarily located in the immune system, and the effects of BIM-018 at this receptor are less well understood.

Effects

The effects of BIM-018 are similar to those of THC and other synthetic cannabinoids, and include euphoria, relaxation, and changes in perception. However, as with all synthetic cannabinoids, the effects can be unpredictable and can vary greatly between individuals. There have been reports of severe adverse effects, including psychosis, seizures, and cardiac arrest, particularly when BIM-018 is used in high doses or in combination with other substances.

Legal Status

The legal status of BIM-018 varies by country. In many countries, including the United States, it is classified as a Schedule I controlled substance, making it illegal to manufacture, distribute, or possess. In other countries, it may be legal or regulated under analogue laws.

See Also

• JWH-018
• Synthetic cannabinoids
• Cannabinoid receptor

BIM-018 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia